Last updated: October 18, 2026
Monopril is the former Bristol-Myers Squibb brand for fosinopril sodium, an angiotensin-converting enzyme inhibitor used to treat hypertension and heart failure. Its commercial value has largely shifted from the branded product to low-cost generic fosinopril. The U.S. product has no meaningful remaining exclusivity profile, no durable brand premium, and limited public financial disclosure. Market demand is sustained by chronic antihypertensive use, but pricing pressure, therapeutic substitution, and competition from lisinopril, enalapril, losartan, and newer cardiovascular therapies constrain revenue.
What is Monopril and who marketed it?
Monopril contains fosinopril sodium, an ACE inhibitor that is converted in vivo to the active compound fosinoprilat. The drug inhibits formation of angiotensin II and reduces aldosterone activity, lowering blood pressure and cardiac afterload.[1]
| Attribute |
Monopril profile |
| Active ingredient |
Fosinopril sodium |
| Drug class |
ACE inhibitor |
| Original sponsor |
Bristol-Myers Squibb |
| U.S. dosage forms |
10 mg, 20 mg, and 40 mg tablets |
| Primary indications |
Hypertension; heart failure as adjunctive therapy |
| FDA approval |
Early 1990s |
| Current commercial model |
Generic fosinopril competition |
| Biologic status |
Not applicable |
| Biosimilar risk |
None |
Monopril was positioned as a once-daily ACE inhibitor with hepatic and renal elimination pathways. That pharmacokinetic profile differentiated fosinopril from some competing ACE inhibitors, but it did not prevent substitution after generic entry.[1]
Monopril HCT combined fosinopril with hydrochlorothiazide. The combination product competed against other ACE inhibitor-thiazide products and generic fixed-dose antihypertensive combinations.
When did Monopril lose market exclusivity?
Monopril lost practical U.S. market exclusivity after the expiration of its primary compound and product protection, followed by FDA approval of generic fosinopril products. The commercially relevant loss of exclusivity occurred in the early 2000s.
| Milestone |
Timing |
Commercial effect |
| Original fosinopril patent family |
Early 1980s filings |
Established compound protection |
| FDA approval of Monopril |
Early 1990s |
Started branded commercial life |
| Monopril HCT approval |
1990s |
Added combination-product coverage |
| Primary patent expiry |
Approximately early 2000s |
Opened market to generic entry |
| Generic fosinopril approvals |
Early 2000s onward |
Removed most branded pricing power |
| Current market |
Generic-dominated |
Low unit prices and multiple suppliers |
Exact patent-by-patent expiration analysis depends on the patent family, terminal disclaimers, patent-term adjustments, and the product being evaluated. The FDA Orange Book should be used for the authoritative listing status of approved U.S. products.[2]
What patents protect Monopril and fosinopril?
The original Monopril estate centered on fosinopril compounds, pharmaceutical compositions, and methods for treating hypertension and cardiovascular disease. The principal commercial protection was compound-level patent protection rather than a durable delivery platform.
Compound and composition patents
The original patent estate included protection for fosinopril and related phosphinate ACE-inhibitor compounds. These patents provided the primary barrier to generic competition during the product’s launch period.
After expiration, generic manufacturers could rely on an abbreviated new drug application pathway if they demonstrated pharmaceutical equivalence, bioequivalence, and compliance with FDA manufacturing requirements.
Formulation patents
Monopril tablets used conventional oral solid dosage technology. The product did not establish a major extended-release, depot, transdermal, injectable, or device-based franchise.
Formulation-related protection, where applicable, was less commercially durable than the original active-ingredient protection. Generic manufacturers could often avoid narrow formulation claims through alternative excipients, tablet processes, or manufacturing approaches.
Method-of-use patents
The principal therapeutic uses were hypertension and heart failure. These indications were clinically established and did not create a strong long-term method-of-use barrier after generic entry.
Because hypertension treatment uses are broad and overlapping, method-of-use patents would have faced practical enforcement limits. Physicians can prescribe generic fosinopril for the same clinical conditions once product-level exclusivity ends.
What is the Orange Book status of Monopril?
The Orange Book is the principal FDA source for approved drug products, therapeutic-equivalence evaluations, patents, and exclusivity information.[2] Monopril’s commercial relevance is limited because the original branded product no longer controls the fosinopril market.
The key Orange Book implications are:
- Monopril’s historical product protections do not preserve a current branded monopoly.
- Generic fosinopril products are available through abbreviated approval pathways.
- Any remaining listed patents must be assessed at the specific NDA and dosage-form level.
- Orange Book listing status does not establish commercial sales or active brand promotion.
Monopril should therefore be analyzed as a legacy brand associated with a mature generic market, not as an actively protected innovator product.
Which companies are challenging Monopril’s market position?
The competitive challenge is primarily generic substitution rather than active Paragraph IV litigation against a current Monopril franchise.
Potential and historical generic competitors include companies that have filed or marketed fosinopril tablets and fosinopril-hydrochlorothiazide combinations. Generic competition in this category commonly includes large U.S. and international suppliers such as Teva, Sandoz, Mylan or Viatris, and other FDA-approved manufacturers, subject to product-specific approval and marketing status.[2]
The main competitive forces are:
| Competitive force |
Effect on Monopril economics |
| Generic fosinopril |
Reduces price and volume for the brand |
| Therapeutic substitution |
Shifts prescriptions to lisinopril, enalapril, or ramipril |
| ARB competition |
Provides alternatives for ACE-inhibitor-intolerant patients |
| Pharmacy benefit management |
Encourages lowest-cost generic dispensing |
| Multiple suppliers |
Increases contracting and price pressure |
| Mature clinical category |
Limits differentiation and premium pricing |
Are there Paragraph IV challenges involving Monopril?
Paragraph IV litigation was commercially relevant during the transition from branded Monopril to generic fosinopril. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.[3]
For Monopril, the current business question is not whether historic generic challenges occurred, but whether any active patent or litigation proceeding can delay generic supply. The product’s long-standing generic availability indicates that historic patent barriers no longer prevent broad market access.
No active, material Paragraph IV dispute should be assumed without checking current FDA Orange Book listings, ANDA litigation records, and federal court dockets. Patent litigation data must be tied to a specific NDA, ANDA, dosage strength, and defendant.
What is Monopril’s FDA regulatory status?
Fosinopril is an FDA-approved prescription ACE inhibitor. The regulatory pathway for generic versions is an ANDA demonstrating bioequivalence to the reference listed drug.[2]
The regulatory profile has several commercial implications:
- No biologics license application is involved.
- Biosimilar approval rules do not apply.
- Generic manufacturers do not need to repeat the full clinical development program required for the original NDA.
- The main regulatory barriers are bioequivalence, chemistry and manufacturing controls, quality systems, labeling, and supply reliability.
- The reference product’s clinical history supports generic substitution but does not protect brand pricing.
Fosinopril products remain subject to ACE-inhibitor class warnings, including fetal toxicity risk, angioedema, hyperkalemia, renal-function effects, and symptomatic hypotension.[1]
How has Monopril’s financial trajectory changed?
Monopril’s financial trajectory followed the standard lifecycle for an oral small-molecule antihypertensive:
- Launch phase: Revenue was supported by branded pricing, physician promotion, and patent protection.
- Growth phase: Prescriptions expanded as ACE inhibitors became standard therapy for hypertension and selected heart-failure patients.
- Maturity phase: Competition from other branded ACE inhibitors and ARBs limited growth.
- Loss-of-exclusivity phase: Generic fosinopril caused rapid price compression and reduced branded volume.
- Post-LOE phase: The economic value moved from the Monopril brand to generic manufacturing and distribution.
Bristol-Myers Squibb’s public reporting does not generally provide a current, standalone Monopril revenue line. As a result, a precise annual Monopril revenue series cannot be established from company filings alone. The product should be treated as a non-core or immaterial contributor to the company’s modern revenue base rather than a current growth asset.[4]
Revenue exposure after generic entry
| Revenue driver |
Expected direction |
| Brand unit volume |
Down materially |
| Net price |
Down sharply |
| Generic unit volume |
Stable to moderate, depending on prescribing |
| Generic gross margin |
Compressed by supplier competition |
| Total category demand |
Relatively stable |
| Innovator contribution |
Minimal |
| Retail pharmacy substitution |
High |
The active ingredient can continue generating low-margin generic sales even after the original brand loses commercial relevance. That distinction matters: market demand for fosinopril may persist while Monopril-specific revenue approaches zero.
How does Monopril compare with competing ACE inhibitors?
| Drug |
Commercial position |
Competitive implication |
| Fosinopril |
Mature generic ACE inhibitor |
Limited differentiation |
| Lisinopril |
High-volume generic ACE inhibitor |
Stronger prescribing and formulary position |
| Enalapril |
Established generic ACE inhibitor |
Competes in hypertension and heart failure |
| Ramipril |
Generic ACE inhibitor with cardiovascular evidence |
Competes for higher-risk cardiovascular patients |
| Perindopril |
Regional and international generic presence |
Relevant in selected markets |
| Losartan |
Generic ARB |
Alternative where cough limits ACE-inhibitor use |
Lisinopril generally has stronger market visibility and broader generic utilization. Fosinopril’s pharmacokinetic profile may support use in selected patients, but that advantage has limited ability to produce a branded price premium.
What manufacturing and intellectual-property barriers remain?
The original compound patent barrier has expired. Remaining barriers are operational rather than strategic patent barriers.
Manufacturing barriers
Generic fosinopril suppliers must manage:
- Active pharmaceutical ingredient sourcing
- Control of impurities and degradation products
- Tablet content uniformity
- Bioequivalence performance
- Stability and packaging
- FDA inspection compliance
- Supply continuity for a low-margin product
Fosinopril is a mature oral solid dosage product. Manufacturing complexity is meaningful but not comparable with sterile injectables, complex biologics, inhaled products, or drug-device combinations.
Intellectual-property barriers
The current IP value is limited. Potential residual protection could involve:
- Narrow formulation claims
- Manufacturing-process claims
- Combination-product claims
- Country-specific patents
- Regulatory exclusivity tied to a particular product or indication
These rights are unlikely to recreate the original Monopril franchise unless they cover a commercially important product with no practical design-around.
What licensing deals affected Monopril?
Monopril was developed and commercialized through Bristol-Myers Squibb’s branded pharmaceutical operations. No major current licensing transaction is central to the product’s market value.
Any historical development, manufacturing, distribution, or regional commercialization arrangements would need to be evaluated by jurisdiction and contract date. They would not materially change the U.S. post-exclusivity analysis unless they transferred active rights, supply obligations, or litigation control.
What generic launch scenarios exist for fosinopril?
Base case: continued generic supply
Multiple suppliers maintain access to fosinopril at low prices. Brand Monopril has little or no commercial influence.
Consolidation case: supplier exit
Low margins or manufacturing issues cause one or more suppliers to exit. Prices may rise temporarily, but other ACE inhibitors remain available as substitutes.
Shortage case
A manufacturing disruption reduces fosinopril availability. Pharmacies and prescribers shift patients to lisinopril, enalapril, ramipril, or an ARB.
Brand revival case
A brand revival would require a new formulation, combination product, specialty indication, or supply-based differentiation. The legacy Monopril tablets alone do not provide a credible basis for a premium relaunch.
How strong is the Monopril patent estate?
The patent estate is weak as a current commercial asset and historically strong only during the pre-generic period.
| Factor |
Assessment |
| Active-ingredient protection |
Expired |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Limited practical value |
| Regulatory exclusivity |
Expired |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Manufacturing complexity |
Low to moderate |
| Current litigation leverage |
Low |
| Brand pricing power |
Minimal |
Key Takeaways
- Monopril is the legacy brand for fosinopril sodium, an oral ACE inhibitor.
- Its principal commercial protection expired in the early 2000s, allowing broad generic entry.
- Current value lies in the generic fosinopril market, not in the Monopril brand.
- The product has no biosimilar exposure because it is a small-molecule drug.
- Generic competition, therapeutic substitution, and pharmacy pricing pressure limit revenue.
- Bristol-Myers Squibb does not provide a meaningful current standalone Monopril revenue disclosure.
- The remaining barriers are manufacturing, quality, supply continuity, and narrow product-specific rights.
- Lisinopril, enalapril, ramipril, and losartan are the main competitive alternatives.
- Any current patent or Paragraph IV assessment must be verified against the specific FDA Orange Book entry and litigation docket.
FAQs
Is Monopril still sold in the United States?
Generic fosinopril is the commercially relevant U.S. product. The legacy Monopril brand has little current market significance compared with generic suppliers.
Is fosinopril more valuable than lisinopril commercially?
No. Fosinopril is a mature generic product, while lisinopril has broader prescribing and formulary penetration in many markets.
Does Monopril have biosimilar competition?
No. Biosimilars apply to biologic products. Fosinopril is a chemically synthesized small molecule and competes through generic ANDA approvals.
Can a company relaunch Monopril at a premium price?
Only with meaningful differentiation, such as a new formulation, fixed-dose combination, specialty indication, or reliable supply advantage. Conventional Monopril tablets have limited premium potential.
What is the main investment risk for a fosinopril manufacturer?
The primary risks are low pricing, supplier consolidation, API disruption, FDA manufacturing action, and substitution by other low-cost ACE inhibitors or ARBs.
References
- U.S. Food and Drug Administration. (n.d.). Monopril (fosinopril sodium) prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (n.d.). Hatch-Waxman and abbreviated new drug applications. FDA.
- Bristol-Myers Squibb Company. (Various years). Annual reports and Securities and Exchange Commission filings. Bristol-Myers Squibb.
